GoAI
Get started
Kubota Pharmaceutical Holdings Co., Ltd. logo

Kubota Pharmaceutical Holdings Co., Ltd.

4596.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥67.00

−¥1.00 · -1.47%

Aug 24, 3:30 PM JST

4596.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Kubota Pharmaceutical Holdings Co., Ltd., an international entity established in Tokyo, Japan, in 2002, focuses on the creation and advancement of a diverse range of pharmaceutical treatments and medical devices. A primary asset in their development pipeline is emixustat hydrochloride, a drug currently undergoing Phase III clinical trials for Stargardt disease and Phase II trials for proliferative diabetic retinopathy. Beyond its pharmaceutical endeavors, the company is also innovating in medical technology, specifically with a patient-centric ophthalmology suite designed for remote retinal monitoring. This advanced suite features both miniature, home-use optical coherence tomography (OCT) devices and high-resolution OCT technology adapted from NASA. Furthermore, Kubota Pharmaceutical Holdings is developing a wearable device aimed at controlling myopia.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Ryo Kubota
Listed since
Dec 6, 2016
Employees
8

Market position

Day range

Current ¥67.00

52-week range

Current ¥67.00

Open
¥68.00
Previous close
¥68.00
Volume
559K
0.2× average
Average volume
2.78M
Average daily volume
Market cap
9.4B JPY
Beta
1.8
Market reference 1
50-day average
¥64.00
+4.69% above average
200-day average
¥82.54
-18.83% below average

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends2542%-7686%-17913%-28141%Gross margin, FY2022: -685.01%Gross margin, FY2023: -148.03%Gross margin, FY2024: -160.41%Gross margin, FY2025: -14.68%Operating margin, FY2022: -25584.27%Operating margin, FY2023: -3493.65%Operating margin, FY2024: -4532.41%Operating margin, FY2025: -4023.14%Net margin, FY2022: -24423.38%Net margin, FY2023: -3734.56%Net margin, FY2024: -4902.17%Net margin, FY2025: -3169.69%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 -685.01%. Gross margin FY2023 -148.03%. Gross margin FY2024 -160.41%. Gross margin FY2025 -14.68%. Operating margin FY2022 -25584.27%. Operating margin FY2023 -3493.65%. Operating margin FY2024 -4532.41%. Operating margin FY2025 -4023.14%. Net margin FY2022 -24423.38%. Net margin FY2023 -3734.56%. Net margin FY2024 -4902.17%. Net margin FY2025 -3169.69%.

Income trends

Revenue

21.34M JPY-21.53%

Operating income

−858.34M JPY+30.35%

Net income

−676.25M JPY+49.26%
Income trends across reported periods308.33M JPY−765.45M JPY−1.84B JPY−2.91B JPYRevenue, FY2022: 8.25M JPYRevenue, FY2023: 39.89M JPYRevenue, FY2024: 27.19M JPYRevenue, FY2025: 21.34M JPYOperating income, FY2021: −2.64B JPYOperating income, FY2022: −2.11B JPYOperating income, FY2023: −1.39B JPYOperating income, FY2024: −1.23B JPYOperating income, FY2025: −858.34M JPYNet income, FY2021: −2.62B JPYNet income, FY2022: −2.02B JPYNet income, FY2023: −1.49B JPYNet income, FY2024: −1.33B JPYNet income, FY2025: −676.25M JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 8.25M JPY. Revenue FY2023 39.89M JPY. Revenue FY2024 27.19M JPY. Revenue FY2025 21.34M JPY. Operating income FY2021 −2.64B JPY. Operating income FY2022 −2.11B JPY. Operating income FY2023 −1.39B JPY. Operating income FY2024 −1.23B JPY. Operating income FY2025 −858.34M JPY. Net income FY2021 −2.62B JPY. Net income FY2022 −2.02B JPY. Net income FY2023 −1.49B JPY. Net income FY2024 −1.33B JPY. Net income FY2025 −676.25M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue21.34M JPY27.19M JPY39.89M JPY8.25M JPY—
Cost of goods sold24.47M JPY70.8M JPY98.93M JPY64.8M JPY59.24M JPY
Gross profit−3.13M JPY−43.61M JPY−59.05M JPY−56.54M JPY−59.24M JPY
Research and development312.21M JPY543.84M JPY788.79M JPY1.51B JPY2.04B JPY
Selling, general, and administrative542.99M JPY644.87M JPY545.68M JPY542.32M JPY544.67M JPY
Operating expenses855.21M JPY1.19B JPY1.33B JPY2.06B JPY2.59B JPY
Interest income1.85M JPY5.73M JPY13.91M JPY18.46M JPY11.24M JPY
Interest expense872K JPY7.4M JPY9.37M JPY11.56M JPY18.17M JPY
Depreciation and amortization—65.65M JPY87.16M JPY58.97M JPY59.24M JPY
Operating income−858.34M JPY−1.23B JPY−1.39B JPY−2.11B JPY−2.64B JPY
Net income−676.25M JPY−1.33B JPY−1.49B JPY−2.02B JPY−2.62B JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-2.32

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates1.12-1.39-3.9-6.41Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 14, 2024: actual -5.87, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 14, 2025: actual -5.89, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual -4.49, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 12, 2025: actual -3.22, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual 0.6, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual -3.58, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 14, 2026: actual -2.58, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual -2.32, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates10.59M7.93M5.26M2.6MQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 14, 2024: actual 7.37M JPY, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 14, 2025: actual 10.03M JPY, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual 7.25M JPY, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 12, 2025: actual 5.53M JPY, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual 4.77M JPY, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 13, 2026: actual 3.06M JPY, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 14, 2026: actual 5.01M JPY, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual 3.06M JPY, estimate —, surprise —, Comparison unavailable.

4596.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,987

-0.34%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,797

+0.57%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,895

0.00%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,210

+0.12%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,858

+0.86%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,406.5

+0.82%

Continue in GoAI

Research 4596.T

research.disclaimer